Dova Pharmaceuticals (NASDAQ:DOVA) posted its earnings results on Thursday. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.12, Fidelity Earnings reports. The business had revenue of $2.93 million for the quarter, compared to analyst estimates of $2.66 million.
Shares of NASDAQ DOVA traded down $2.41 during midday trading on Friday, reaching $16.89. The stock had a trading volume of 647,924 shares, compared to its average volume of 144,409. The company has a market capitalization of $527.66 million, a P/E ratio of -12.06 and a beta of 0.87. Dova Pharmaceuticals has a twelve month low of $16.63 and a twelve month high of $37.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.14 and a current ratio of 13.19.
Several equities research analysts recently commented on DOVA shares. Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 target price on the stock in a research report on Wednesday, October 10th. Jefferies Financial Group reiterated a “buy” rating and set a $40.00 target price on shares of Dova Pharmaceuticals in a research report on Sunday, July 15th. BidaskClub upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 31st. Leerink Swann cut their target price on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 4th. Finally, Raymond James initiated coverage on shares of Dova Pharmaceuticals in a research report on Wednesday, August 29th. They set an “outperform” rating and a $44.00 target price on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $33.20.
In other news, CEO Alex Sapir purchased 21,700 shares of the company’s stock in a transaction dated Tuesday, August 14th. The shares were purchased at an average price of $22.83 per share, for a total transaction of $495,411.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 55.50% of the stock is currently owned by insiders.
A hedge fund recently raised its stake in Dova Pharmaceuticals stock. Bank of New York Mellon Corp raised its position in Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 196.8% during the second quarter, according to its most recent filing with the SEC. The firm owned 46,374 shares of the company’s stock after purchasing an additional 30,750 shares during the period. Bank of New York Mellon Corp owned 0.16% of Dova Pharmaceuticals worth $1,387,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 36.64% of the company’s stock.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Further Reading: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.